- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05112887
Osteopathic Manipulative Therapy Effects on Prolonged Post-COVID Olfactory Dysfunction
The goal of this project is to determine the efficacy of a treatment method that increase a participants sense of smell after suffering from COVID-19 related decline in smell. Participants have to be greater than 14 days from positive COVID-19 test and still have a decreased sense of smell. https://jaoa.org/article.aspx?articleid=2765119 this article is a review of literature regarding why OMT can have a positive effect on individuals suffering from COVID-19
Anosmia: Complete loss of smell Hyposmia: Decrease in smell
Study Overview
Status
Intervention / Treatment
Detailed Description
The goal of this project will be to determine if OMT can return the sense of smell to participants who previously contracted COVID-19.
Participants will have to email a positive COVID-19 test result >14 days prior to MS861918@ohio.edu. There will be a correspondence with the participant to ask them if they feel their sense is still decreased or absent and then candidacy for study will be determined.
20 participants will be divided randomly into sham OMT treatment groups and real OMT treatments. 10 in each group
Participants will rate on a scale of 0-10 (0 being no smell, and 10 being pre-COVID19 exposure smell) the ability to smell the following items blindfolded pre-treatment as well as attempt to identify the substance:
These will be performed with
- Perfume
- Red Onion (sliced)
- Bourbon
- Orange
Participants in the sham treatment group will receive a non-osteopathic approach to treatment, which will consist of general palpation of head/neck/shoulder region. Participants in the Osteopathic Manipulation Therapy (OMT) group will receive:
- Rib raising
- Suboccipital Release
- Thoracic Inlet Release
- Miller Thoracic Pump
- Pedal Pump
- Cranial OMT, Performed Indirect Vault hold at conclusion
Stevan Walkowski, D.O. will be providing treatment to both the OMT and Sham group.
Participants will rate on a scale of 0-10 (0 being no smell, and 10 being pre-COVID19 exposure smell) to smell the following items blindfolded pre-treatment as well as attempt to identify the substance 10 min post-treatment:
- Perfume
- Red Onion (sliced)
- Bourbon
- Orange
Participants will be debriefed following the research procedure. They will be informed of potential side effects that is listed in the risks or discomfort category and will be encouraged to drink water following treatment.
Side effects from sham treatment group: Frustration of not re-acquiring sense of smell
Side effects from OMT treatment group: Headache, dizziness, increase secretion (diarrhea, diuresis) from increase in fluid flow, frustration of not re-acquiring sense of smell
Participants in both groups will be told of the side effects of the OMT treatment group and will be encouraged to drink water following treatment.
Benefits from sham treatment group: none
Benefits from OMT treatment group: May have an increase sense of smell post-treatment
Multiple post-COVID19 individuals who lost sense of smell continue to have a decrease sense of smell after surviving the illness. These people have a decreased ability to smell food, drinks and enjoy shared human experiences which can lead to isolation. Individuals who have a decrease sense of smell are also in increased danger due to not being able to smell hazardous events around them i.e. smoke from a fire, gas filling their house from a leaking gas stove, spoiled food etc..
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Dublin, Ohio, United States, 43016
- Ohio University Heritage College of Medicine - Dublin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Positive COVID test greater than 14 days prior
- Self-identify a decrease in smell after the resolution of their infection
Exclusion Criteria:
- Complete smell recovery after resolution of infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: OMT Group
The OMT protocol treatment sequence was performed in the following order: 1. Rib raising from a seated position 2. Suboccipital Release from a supine position 3. Thoracic Inlet Release 4. Miller Lymphatic Pump 5. Pedal Pump 6. Suboccipital Release 7. Cranial Sinus Effleurage
1. Appreciate cranial respiratory motion 2. Diagnose cranial strain pattern 3. Place cranial strain pattern into position of ease |
Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.
Other Names:
|
|
Placebo Comparator: Placebo/Light Touch/Sham Group
Participants in the sham/placebo group were lightly touched in equivalent positions to the OMT treatments.
First, sham participants were lightly touched on the thoracic cage while seated, followed by light touch of the neck, chest, feet, and cranium while supine.
The length of light touch was modeled after the approximate time needed for the OMT matching each treatment region.
Each treatment sequence lasted about 20 minutes in total.
|
Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Smell Intensity
Time Frame: 10 minutes will elapse between treatment and post-treatment smell testing.
|
Participants will smell the 4 substances blindfolded and will rank each one from 0-10, 0 being no smell and 10 be pre-COVID smell.
Participant will then be treated either with OMT or placebo and then asked to resmell the same 4 smell substances and rank them on the same scale.
|
10 minutes will elapse between treatment and post-treatment smell testing.
|
|
Smell Identification
Time Frame: 10 minutes will elapse between treatment and post-treatment smell testing.
|
Participants will smell the 4 substances blindfolded and attempt to identify the smells.
Participants will then receive treatment either OMT or Placebo and will smell the same 4 substances while attempting to identify them again.
Correct answers were given a score of "1" and incorrect answers were given a smell of "0"
|
10 minutes will elapse between treatment and post-treatment smell testing.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quantitative smell experience
Time Frame: 10 minutes will elapse between treatment and post-treatment smell testing.
|
Participants were interviewed prior to pre-treatment smell testing to gain a further understanding of how this ailment affects participants on an individual level.
|
10 minutes will elapse between treatment and post-treatment smell testing.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Steven Walkowski, DO, Ohio University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-F-13
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV2 Infection
-
Centre Hospitalier Universitaire DijonCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Meshalkin Research Institute of Pathology of CirculationUnknown
-
Collegium Medicum w BydgoszczyRecruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
Collegium Medicum w BydgoszczyActive, not recruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
University Hospital, LilleFondation Santé RoquetteCompleted
-
University of AarhusCompleted
-
University Hospital, LilleFondation Santé RoquetteWithdrawn
-
Medical University of ViennaWithdrawnSars-CoV2 | Prophylaxis | Infection Viral | Healthcare Worker
-
Rutgers, The State University of New JerseyNational Institute of Dental and Craniofacial Research (NIDCR)CompletedSARS-CoV2 InfectionUnited States
Clinical Trials on Osteopathic Manipulative Therapy
-
College Osteopathique de Provence Aix-MarseilleUniversity Hospital, MarseilleRecruitingSickle Cell DiseaseFrance
-
University of LouisvilleRecruitingLong-COVID | Long COVID Syndrome | PASCUnited States
-
Pacific Northwest University of Health SciencesCompletedBack Pain | Somatic Dysfunction | Lumbar Pain | Thoracic Pain | Fascial DistortionUnited States
-
Alanya Alaaddin Keykubat UniversityCompletedMigraine DisordersTurkey
-
Hackensack Meridian HealthCompletedHeadache | Post-Concussion SyndromeUnited States
-
Western University of Health SciencesCompletedLabyrinthitis | Vertigo | Benign Paroxysmal Positional Vertigo | DizzinessUnited States
-
Studio Osteopatico Busto ArsizioRecruitingGastro-oesophageal Reflux DiseaseItaly
-
Université du Québec a MontréalCollège d'Études Ostéopathiques de MontrealCompletedHeart Rate VariabilityCanada
-
Rio de Janeiro State UniversityEstácio S.A.Completed
-
New York Institute of TechnologyCompletedDistorted; Balance | Post-Concussion SymptomsUnited States